De-Nol, 120 mg 32 pcs.

De-Nol is gastroprotective, antiulcer, antibacterial.

Pharmacodynamics

An anti-ulcer agent with bactericidal activity against Helicobacter pylori. It also has anti-inflammatory and astringent activity. In the acidic environment of the stomach insoluble bismuth oxychloride and citrate are precipitated; chelated compounds with protein substrate are formed in the form of a protective film on the surface of ulcers and erosions.

Augmenting the synthesis of PGE, mucus formation and bicarbonate secretion, stimulates the activity of cytoprotective mechanisms, increases the resistance of the gastrointestinal mucosa to pepsin, hydrochloric acid, enzymes and salts of bile acids. Leads to the accumulation of epidermal growth factor in the defect area. Reduces the activity of pepsin and pepsinogen.

Pharmacokinetics

Bismuth subcitrate is practically not absorbed from the GI tract. It is excreted mainly with the feces. A small amount of bismuth entered into the plasma is excreted by the kidneys.

Indications

Peptic ulcer of the stomach and duodenum in the acute phase, incl. associated with Helicobacter pylori;
chronic gastritis and gastroduodenitis in the acute phase, incl. associated with Helicobacter pylori;
irritable bowel syndrome, which occurs predominantly with symptoms of diarrhea;
functional dyspepsia not associated with organic gastrointestinal diseases.

Pharmacological effect

De-Nol – gastroprotective, antiulcer, antibacterial.

Pharmacodynamics

Antiulcer agent with bactericidal activity against Helicobacter pylori. It also has anti-inflammatory and astringent effects. In the acidic environment of the stomach, insoluble bismuth oxychloride and citrate are precipitated, and chelate compounds are formed with the protein substrate in the form of a protective film on the surface of ulcers and erosions.

By increasing the synthesis of PGE, mucus formation and bicarbonate secretion, it stimulates the activity of cytoprotective mechanisms, increases the resistance of the gastrointestinal mucosa to the effects of pepsin, hydrochloric acid, enzymes and bile salts. Leads to the accumulation of epidermal growth factor in the defect area. Reduces the activity of pepsin and pepsinogen.

Pharmacokinetics

Bismuth subcitrate is practically not absorbed from the gastrointestinal tract. It is excreted mainly in feces. A small amount of bismuth entering the plasma is excreted from the body by the kidneys.

Special instructions

The drug should not be used for more than 8 weeks. It is also not recommended to exceed the established daily doses for adults and children during treatment. During treatment with De-Nol®, you should not use other drugs containing bismuth. At the end of a course of treatment with the drug in recommended doses, the concentration of the active substance in the blood plasma does not exceed 3–58 mcg/l, and intoxication is observed only at concentrations above 100 mcg/l.

When using De-Nol®, stool may turn dark due to the formation of bismuth sulfide. Sometimes there is a slight darkening of the tongue.

Active ingredient

Bismuth tripotassium dicitrate

Composition

Creamy white, round, biconvex film-coated tablets with “gbr 152” embossed on one side and a square graphic with broken sides and rounded corners embossed on the other side, odorless or with a slight odor of ammonia.

1 tab.
bismuth tripotassium dicitrate
304.6 mg,
which corresponds to the content of bismuth oxide
120 mg

Excipients:

corn starch – 70.6 mg,

povidone K30 – 17.7 mg,

potassium polyacrylate – 23.6 mg,

macrogol 6000 – 6 mg,

magnesium stearate – 2 mg.

Shell composition:

opadry OY-S-7366 (hypromellose 5 mPa s – 3.2 mg, macrogol 6000 – 1.1 mg).

Contraindications

Individual intolerance to the drug;
severe renal dysfunction;
pregnancy;
lactation

Side Effects

From the digestive system: nausea, vomiting, more frequent bowel movements, and constipation may occur. These phenomena are not dangerous to health and are temporary.

Allergic reactions: skin rash, skin itching.

With long-term use in high doses, encephalopathy associated with the accumulation of bismuth in the central nervous system.

Interaction

For half an hour before and after taking De-Nol®, it is not recommended to take other drugs internally, as well as take food and liquids, in particular antacids, milk, fruits and fruit juices.

Overdose

Symptoms (with long-term use of doses exceeding the recommended): impaired renal function. These symptoms are completely reversible when De-Nol® is discontinued.

Treatment: gastric lavage, administration of activated charcoal and saline laxatives. Further treatment should be symptomatic. In case of impaired renal function, accompanied by a high level of bismuth in the blood plasma, the use of complexing agents – dimercaptosuccinic and dimercaptopropanesulfonic acids. In case of severe renal dysfunction, hemodialysis is indicated.

Storage conditions

The drug should be stored at a temperature of 15° to 25°C.

Shelf life

4 years.

Manufacturer

ZiO-Zdorovye CJSC, Russia